Cancers (Jul 2023)

The Prevalence and Molecular Landscape of Lynch Syndrome in the Affected and General Population

  • Laura Roht,
  • Piret Laidre,
  • Mikk Tooming,
  • Neeme Tõnisson,
  • Margit Nõukas,
  • Miriam Nurm,
  • Estonian Biobank Research Team,
  • Hanno Roomere,
  • Kadri Rekker,
  • Kadri Toome,
  • Olga Fjodorova,
  • Ülle Murumets,
  • Ustina Šamarina,
  • Sander Pajusalu,
  • Anu Aaspõllu,
  • Liis Salumäe,
  • Kristina Muhu,
  • Jaan Soplepmann,
  • Katrin Õunap,
  • Tiina Kahre

DOI
https://doi.org/10.3390/cancers15143663
Journal volume & issue
Vol. 15, no. 14
p. 3663

Abstract

Read online

Background: Lynch syndrome (LS) is the most frequent genetically pre-disposed colorectal cancer (CRC) syndrome, accounting for 2–3% of all CRC cases. In Estonia, ~1000 new cases are diagnosed each year. This retroactive and prospective study aimed to estimate the prevalence of LS and describe disease-causing variants in mismatch repair (MMR) genes in a diagnostic setting and in the Estonian general population. Methods: LS data for the diagnostic cohort were gathered from 2012 to 2022 and data for the general population were acquired from the Estonian Biobank (EstBB). Furthermore, we conducted a pilot study to estimate the improvement of LS diagnostic yield by raising the age limit to >50 years for immunohistochemistry analysis of MMR genes. Results: We estimated LS live birth prevalence between 1930 and 2003 in Estonia at 1:8638 (95% CI: 1: 9859–7588). During the study period, we gathered 181 LS individuals. We saw almost a six-fold increase in case prevalence, probably deriving from better health awareness, improved diagnostic possibilities and the implementation of MMR IHC testing in a broader age group. Conclusion: The most common genes affected in the diagnostic and EstBB cohorts were MLH1 and PMS2 genes, respectively. The LS diagnosis mean age was 44.8 years for index cases and 36.8 years (p = 0.003) for family members. In the MMR IHC pilot study, 29% had LS.

Keywords